Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
A Systematic Review of Treatment Outcome in Patients with Dopa‐responsive Dystonia (DRD) and DRD‐Plus
View through CrossRef
AbstractBackgroundDopa‐responsive dystonia (DRD) and DRD‐plus are inherited metabolic disorders of the dopamine synthetic pathway that have considerable clinical, biochemical, and genetic heterogeneity. Dopamine is the main deficient neurotransmitter; however, a deficiency in norepinephrine and serotonin can coexist, depending on the gene and its degree of defect. Therefore, even though levodopa is the mainstay of therapy, response to levodopa can be suboptimal and, thus, other drugs are tried.Methods and ResultsThe authors searched for reports of DRD and DRD‐plus and reviewed the drugs used, their response and side effects, and neurologic outcomes, including motor and cognition. Based on the current results, a recommended treatment plan is presented according to the type of enzyme defect in patients with DRD and DRD‐plus.ConclusionsIt is important to recognize the features of DRD and DRD‐plus, because many of them have a good clinical response to the appropriate treatment. The aim of this review is to help guide clinicians with planning treatment for patients with DRD and DRD‐plus.
Title: A Systematic Review of Treatment Outcome in Patients with Dopa‐responsive Dystonia (DRD) and DRD‐Plus
Description:
AbstractBackgroundDopa‐responsive dystonia (DRD) and DRD‐plus are inherited metabolic disorders of the dopamine synthetic pathway that have considerable clinical, biochemical, and genetic heterogeneity.
Dopamine is the main deficient neurotransmitter; however, a deficiency in norepinephrine and serotonin can coexist, depending on the gene and its degree of defect.
Therefore, even though levodopa is the mainstay of therapy, response to levodopa can be suboptimal and, thus, other drugs are tried.
Methods and ResultsThe authors searched for reports of DRD and DRD‐plus and reviewed the drugs used, their response and side effects, and neurologic outcomes, including motor and cognition.
Based on the current results, a recommended treatment plan is presented according to the type of enzyme defect in patients with DRD and DRD‐plus.
ConclusionsIt is important to recognize the features of DRD and DRD‐plus, because many of them have a good clinical response to the appropriate treatment.
The aim of this review is to help guide clinicians with planning treatment for patients with DRD and DRD‐plus.
Related Results
Phylogenetic evidence suggests a later origin of the DRD
2l
and DRD
4rs
dopamine receptor gene lineages
Phylogenetic evidence suggests a later origin of the DRD
2l
and DRD
4rs
dopamine receptor gene lineages
Dopamine receptors are integral membrane proteins whose endogenous ligand is dopamine. They play a fundamental role in the central nervous system and dysfunction of dopaminergic ne...
Evolution of dopamine receptors: phylogenetic evidence suggests a later origin of the DRD
2l
and DRD
4rs
dopamine receptor gene lineages
Evolution of dopamine receptors: phylogenetic evidence suggests a later origin of the DRD
2l
and DRD
4rs
dopamine receptor gene lineages
Dopamine receptors are integral membrane proteins whose endogenous ligand is dopamine. They play a fundamental role in the central nervous system and dysfunction of dopaminergic ne...
Potentiation of latent inhibition by haloperidol and clozapine is attenuated in Dopamine D2 receptor (Drd-2)-deficient mice: Do antipsychotics influence learning to ignore irrelevant stimuli via
both
Drd-2 and non-D
Potentiation of latent inhibition by haloperidol and clozapine is attenuated in Dopamine D2 receptor (Drd-2)-deficient mice: Do antipsychotics influence learning to ignore irrelevant stimuli via
both
Drd-2 and non-D
Whether the dopamine Drd-2 receptor is necessary for the behavioural action of antipsychotic drugs is an important question, as Drd-2 antagonism is responsible for their debilitati...
L-Dopa Treatment in Parkinson’s Disease
L-Dopa Treatment in Parkinson’s Disease
Double-blind and non-blind therapeutic trials of orally administered L-Dopa in the long-term treatment of Parkinsonism were carried out with 126 patients. For correlative studies t...
Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study
Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study
Although there are several reports of the significant efficacy of zolpidem for treating dystonia, zolpidem is still considered an anecdotal treatment. Here, we evaluated the effica...
Decoding Dystonia in Autoimmune Disorders: A Scoping Review
Decoding Dystonia in Autoimmune Disorders: A Scoping Review
Background: Dystonia is a common hyperkinetic movement disorder observed in various genetic, infective, drug-induced, and autoimmune disorders. Autoimmune disorders can present wit...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Access to drugs for rare diseases (DRD) in Canada: a comprehensive review of the provincial DRD-specific programs
Access to drugs for rare diseases (DRD) in Canada: a comprehensive review of the provincial DRD-specific programs
Access to drugs for rare diseases (DRDs) in Canada depends largely on the province of living and the specific disease. The federal government and each of the ten provincial governm...